FDA Recommends Pre-BLA Meeting for Rezolute’s Congenital…

Event summary

FDA recommended a pre-BLA meeting for Rezolute’s ersodetug despite Phase 3 sunRIZE trial missing primary endpoint.
Key secondary endpoints showed clinically relevant improvements in hypoglycemia despite statistical insignificance.
Rezolute expects topline results from the Phase 3 upLIFT study for tumor HI this quarter.
FDA did not opine on approvability, noting determination would come during formal BLA review.
Open-label extension phase of sunRIZE study ongoing with high retention and continued glycemic control.

The big picture

Rezolute’s situation highlights the challenges of developing treatments for ultra-rare diseases, where traditional clinical endpoints may not fully capture therapeutic benefits. The FDA’s willingness to engage in a pre-BLA meeting despite trial misses suggests a nuanced approach to evaluating drugs for conditions with significant unmet medical needs. The outcome will be closely watched as a potential precedent for other rare disease therapies facing similar regulatory hurdles.

What we're watching

Regulatory Strategy: Whether FDA’s recommendation for a pre-BLA meeting signals a potential path to approval despite trial shortcomings.
Clinical Efficacy: How the ongoing open-label extension data may influence future regulatory discussions.
Pipeline Progress: The impact of upLIFT study results on Rezolute’s overall BLA submission strategy for both congenital and tumor HI.